Yes, precisely.
You would also want to adjust for between group differences. For example, more difficult to treat patients in the placebo group could heavily skew the data in favor of treatment arm, and vice versa.
Monotherapy endpoint not signifcant at 95% (p = 0.06) compared to no therapy as per first P2 data announcement. Once again, need to understand the severity of depression to conceptualize findings.
Monotherapy data indicates effect declines from 6 weeks to 10 weeks, but combination data suggests improvements from 6 to 10 weeks. Pretty clear that the improvement in effect is related to SoC and not treatment.
- Forums
- ASX - By Stock
- Ann: ACW updated depression trial results and implications
Yes, precisely. You would also want to adjust for between group...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
-0.005(11.1%) |
Mkt cap ! $108.4M |
Open | High | Low | Value | Volume |
4.5¢ | 5.2¢ | 4.0¢ | $1.876M | 40.43M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 40842 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 716560 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500000 | 0.040 |
5 | 1654665 | 0.039 |
7 | 1081338 | 0.038 |
4 | 639000 | 0.037 |
8 | 666414 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 716560 | 3 |
0.042 | 23836 | 2 |
0.043 | 139191 | 5 |
0.044 | 278516 | 3 |
0.045 | 661633 | 6 |
Last trade - 14.01pm 27/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online